Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129177 | 0.88 | KDM4C (0.44) | HDAC8ERBB2KDM4CMAPTKMT2A | |
| SCHEMBL9917430 | 0.86 | HDAC6 (0.57) | HDAC8ERBB2HDAC6MAPTKMT2A | |
| SCHEMBL1129002 | 0.85 | HDAC8 (0.48) | HDAC8ERBB2HDAC6KMT2AALDH1A1 | |
| SCHEMBL16772292 | 0.85 | SMN1; SMN2 (0.45) | HDAC8ERBB2HDAC6KMT2AMEN1 | |
| SCHEMBL20680673 | 0.82 | HDAC6 (0.42) | HDAC8ERBB2KDM4CHDAC6ALDH1A1 | |
| SCHEMBL662061 | 0.81 | IDO1 (0.45) | ERBB2HDAC6MAPTKMT2AALDH1A1 | |
| SCHEMBL17602097 | 0.81 | ESR2 (0.56) | ERBB2KDM4CHDAC6LMNAALDH1A1 | |
| SCHEMBL14327125 | 0.81 | ERBB2 (0.45) | HDAC8ERBB2KDM4CHDAC6MAPT | |
| SCHEMBL13042 | 0.81 | NPC1 (0.50) | ERBB2KDM4CMAPTKMT2ALMNA | |
| SCHEMBL8553183 | 0.81 | ADORA2A (0.48) | ERBB2KDM4CHDAC6MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254093-A1 | GPR35 Agonist Compounds | NXERA PHARMA UK LIMITED (GB) | 2024-08-01 | — | — | US | disclosed |
| EP-4326708-A1 | GPR35 AGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2024-02-28 | — | — | EP | disclosed |
| CN-117529472-A | GPR35 agonist compounds | 赫普泰雅治疗有限公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2022224212-A1 | GPR35 AGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-27 | — | — | WO | disclosed |
| WO-2022224212-A1 | GPR35 AGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-27 | — | — | WO | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| CN-102046179-B | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS INC | 2015-01-14 | — | — | CN | disclosed |
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431695-B2 | Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | BAYER HEALTHCARE AG (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| CN-102046179-A | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS INC | 2011-05-04 | — | — | CN | disclosed |
| EP-2282742-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Infinity Pharmaceuticals, Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-1945222-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | Bayer HealthCare AG (DE) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056170-A2 | PYRROLO[2,1-F] [1,2,4] TRIAZIN-4-YLAMINES IGF-1R KINASE INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER HYPERPROLIFERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254093-A1 | GPR35 Agonist Compounds | GPR35, GPR119, GPR68 | HDAC8 1207/4885ERBB2 1126/4885KDM4C 4669/4885 |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | HDAC8 769/4885ERBB2 2259/4885KDM4C 1813/4885 |
| US-20110294776-A1 | Pyrrolo[2,1-F] [1,2,4] Triazin-4-Ylamines IGF-1R Kinase Inhibitors for the Treatment of Cancer and Other Hyperproliferative Diseases | IGF1R, FGFR1, IGFBP1 | HDAC8 1757/4885ERBB2 10/4885KDM4C 1593/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | HDAC8 769/4885ERBB2 2259/4885KDM4C 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.